Biomarkers for subtypes of cervical cancer
AssigneeOslo Universitetssykehus Hf
InventorsHeidi Lyng, Malin Lando
Life of this patent
Estimating the term…
Abstract
The present invention relates to biomarkers for chemoradioresistant subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer.
Claims9
A method for detectably labelling a set of gene products from a human cervical cancer sample comprising:
- isolating RNA from a human cervical cancer sample from a patient with locally advanced cervical cancer and reverse transcribing said isolated RNA to provide complementary DNA corresponding to at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products
- amplifying said complementary DNA by polymerase chain reaction with primers specific for complementary DNA corresponding to at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products in the presence of a probe to provide detectably labeled amplified complementary DNA;
- quantitating the expression of said at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products;
- and
- providing a prognosis based on the expression of said at least three gene products selected from the group consisting of RYBP, GBE1, ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B and PRDM15 gene products.
Dependencies are inferred from the claim text.